Drug class or analogue
ANP Analogue
A class of engineered natriuretic peptides designed to activate guanylyl cyclase-A and promote vasodilation, natriuresis and blood-pressure reduction.
Evidence confidence
Human
2/5
Some human clinical evidence
1 citation
Animal
Not yet assessed
Trust Engine review pending.
Mechanistic
Not yet assessed
Trust Engine review pending — see editorial links below.
Editorial evidence links exist, but this category has not yet completed Trust Engine assessment.
Safety
Not yet assessed
Trust Engine review pending.
Claimed uses
- Insufficient
Mechanisms
- not-yet-documented
- Nitric oxide / blood flow
Safety notes
Possible risks include hypotension, dizziness, syncope, altered renal perfusion and electrolyte or fluid changes. Safety cannot be generalised across analogues.
Regulation
- No general ANP analogue class approval. Individual products may be investigational or licensed only for specific jurisdictions and indications.
References
Last reviewed
11 July 2026